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Background: Level 1 evidence supports carotid endarterectomy (CEA) as the standard treatment for severe (>70% lumen
reduction) carotid stenosis in asymptomatic patients, though its safety and efficacy in high-risk patients remain
controversial. Long-term survival and stroke-free survival after CEA may guide decisions concerning this procedure for
asymptomatic patients, but this outcome has only been considered in few reports outside the large randomized trial
setting. This study analyzed long-term survival and stroke-free survival after CEA and the impact of risk factors in a
consecutive series of asymptomatic patients, including those with medical comorbidities and particular anatomical
features believed to increase the perioperative morbidity and mortality of CEA.
Methods: For over 10 years, data were prospectively collected for all patients who underwent CEA for asymptomatic severe
carotid disease at our institution. All CEAs performed by the same surgeon involved eversion technique, with patients
under deep general anesthesia and continuous perioperative electroencephalographic (EEG) monitoring for selective
shunting. All patients had neurological follow-up and duplex ultrasound at 1, 6, and 12 months, and yearly thereafter.
A complete follow-up (mean, 6.1 years; range, 0.1 to 10.6 years) was obtained in 348 patients (93%) with an overall 365
CEAs (93%). Survival analyses were performed using Kaplan-Meier life tables.
Results: Among 374 patients undergoing 391 CEAs, there were no perioperative deaths or strokes. There were 17 (4.8%)
late deaths, mainly cardiac-related (70%), and 2 (0.5%) non-fatal strokes. At 5 and 10 years, survival was 96.3% and
85.7%, and stroke-free survival was 95.6% and 84.8%, respectively. At multivariate analysis, diabetes mellitus (P  .002)
and cardiac disease (P  .005) were independent predictors of a shorter long-term survival.
Conclusions: Eversion CEA proved safe and effective in a series of patients with asymptomatic severe carotid disease
representing the typical population of daily clinical practice. Although long-term results were extremely favorable,
excellent stroke-free survival was not translated into a longer patient survival. ( J Vasc Surg 2007;46:265-70.)Multicenter, randomized clinical trials (RCTs) have
shown that carotid endarterectomy (CEA) significantly re-
duces the long-term risk of stroke due to severe (70% lumen
reduction) carotid disease in asymptomatic patients,1,2 result-
ing inmoreCEAs being performedworldwide for asymptom-
atic disease, though the benefits were less striking than those
seen in RCTs on CEA in symptomatic patients.3,4 Despite
RCTs providing the basis for guidelines for CEA with the
assumption that the morbidity and mortality rates be better
than those of the disease’s natural history,5 large institution-
based studies can provide additional valuable information by
recruiting patients whomight not have met the specific inclu-
sion criteria for RCTs. Indeed, asymptomatic patients with
medical comorbidities (significant cardiac disease, chronic ob-
structive pulmonary disease, chronic kidney disease, and old
age) or particular anatomical features (contralateral carotid
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doi:10.1016/j.jvs.2007.03.043occlusion, high carotid bifurcation, or other anticipated tech-
nical difficulties) were excluded from the RCTs, even though
they account for a substantial portion of the general popula-
tion seen in everyday clinical practice. Controversy remains,
however, as to whether and which specific clinical or anatom-
ical variables are associated with worse results after CEA in
such patients.6-8
Although many authors have documented the progres-
sion of asymptomatic carotid lesions in unoperated pa-
tients9,10 and in those who had CEA for symptomatic or
asymptomatic contralateral severe lesions,11,12 outside the
RCT setting, long-term survival and stroke-free survival
after CEA for asymptomatic carotid disease have been
examined only partially and in a handful of studies,13-17
most of which failed to analyze outcome selectively for
different indications.14-16
Since long-term outcomes are an essential parameter in
the evaluation of this prophylactic procedure, we designed
this study to analyze long-term survival and stroke-free
survival in a consecutive series of patients who underwent
CEA for asymptomatic carotid disease, including those
with medical comorbidities and anatomical features be-
lieved to increase the risk of CEA.6
PATIENTS AND METHODS
Demographic and clinical data for all patients with
asymptomatic carotid disease, including those who had
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events and non-specific symptoms6 months, who under-
went CEA at our institution over a 10-year period (1995-
2004) were prospectively entered into a computerized da-
tabase according to the recommendations of the
Asymptomatic Carotid Atherosclerosis Study (ACAS).1 Pa-
tients scheduled for CEA with concomitant coronary artery
bypass grafting or with associated supra-aortic trunk lesions
requiring concurrent surgery, and patients requiring pro-
cedures for recurrent disease were ruled out. Written in-
formed consent was obtained from all patients involved in
this study, which was approved by our Institutional Ethics
Review Board.
The patients’ demographic and clinical data were re-
corded on a standardized form, including potential risk
factors for atherosclerosis, other anatomical and clinical
variables, details of the operation and hospital stay. Smok-
ing was defined as past (a history of smoking for at least 10
years before quitting more than 15 years ago) or current
cigarette smoking (patients who had smoked for more than
10 years and continued to do so as at the time of surgery).
Hyperlipidemia was recorded for serum cholesterol
levels higher than 200 mg/dL or a prior diagnosis, includ-
ing the use of a lipid-lowering drug. Diabetes mellitus was
diagnosed clinically before or at the time of admission for
surgery: this category included both type 1 and type 2
diabetes mellitus. Hypertension was recorded on the
strength of a clinical diagnosis, including the current use of
antihypertensive therapy. Cardiac disease included any of
the following: a history of myocardial infarction (MI), atrial
fibrillation, congestive heart failure (CHF), angina pectoris,
coronary artery bypass, surgery for valve disease or signs of
ischemia on an electrocardiogram, and nitrate therapy.
Chronic kidney disease was defined as a serum creatinine
level higher than 1.5 mg/dL in either conservative or
dialysis treatment. Pulmonary disease was defined as a
history of chronic restrictive or obstructive disease based on
pulmonary function tests, pulmonary embolism, and prior
lobectomy or pneumonectomy. The diagnosis of carotid
lesion was based on preoperative digital subtraction an-
giography (DSA) during the earlier part of this study (used
with decreasing frequency over the years), while duplex
ultrasound scan was the only preoperative carotid imaging
study performed in most patients from mid-1998 onwards,
combined in selected patients (patients who either had a
pseudo-occlusion on duplex ultrasound scan or a stenosis
of the internal carotid intracranial segment detected by
transcranial Doppler sonography) with magnetic resonance
angiography (MRA), contrast-enhanced MRA, or DSA.
Stenosis was classified as 60% to 69% (peak systolic velocity
[PSV] 130 cm/s; peak diastolic velocity [PDV] 40-110
cm/s; peak systolic velocity of internal carotid artery/peak
systolic velocity of common carotid artery [carotid ratio]
3.2 - 4.0); 70% to 79% (PSV 210 cm/s; PDV 110-140
cm/s; ratio 4.0); or 80% to 99% (PSV 210 cm/s; PDV
140 cm/s; ratio 4.0). The velocity criteria not the
features of the plaque were taken into account for CEA
decision. All patients were on antiplatelet therapy. All pa-tients with diabetes, hyperlipidemia, and/or hypoechoic
plaques were on statin therapy. Preoperative patient prep-
aration was standardized.
All CEA procedures involved eversion technique: the
details of this procedure have been published elsewhere.18
All CEAs were performed by the same surgeon with pa-
tients under deep general anesthesia and continuous peri-
operative electroencephalographic (EEG) monitoring for
selective shunting. Shunting criteria were based exclusively
on EEG changes consistent with cerebral ischemia. No
completion imaging studies were performed. None of the
CEA procedures considered in this series were aborted or
incomplete, and none of the patients were refused CEA for
technical reasons emerging during surgery.
Patients were usually monitored in the recovery room
for 2 hours until their blood pressure and neurological
status were considered acceptable, then they were trans-
ferred to a regular nursing unit specializing in vascular care
andmonitored for the next 12 to 24 hours after surgery. All
patients with severe headache were observed for hyperper-
fusion syndrome, and hypertension was treated aggres-
sively. Most patients were discharged 48 to 72 hours after
CEA.
Surveillance protocol. After discharge, visiting nurses
monitored the patients’ blood pressure and neurological
status. All survival patients systematically underwent phys-
ical and neurological assessments by a consultant neurolo-
gist, and duplex ultrasound scans performed by two expe-
rienced technologists, 1, 6, and 12 months and then yearly
after CEA. Neurological events were always classified by the
consultant neurologist as transient ischemic attack (TIA); (ie,
temporary hemispheric symptoms lasting no more than 24
hours, with complete recovery), amaurosis fugax (transient
monocular visual loss), or stroke (minor: minimal, stabi-
lized focal neurological deficit of acute onset and persisting
more than 24 hours, but not causing disability or any
significant impairment in activities of daily living, or major:
a focal neurological deficit lasting more than 30 days and
inducing a change in lifestyle). Brain imaging (computed
tomography or magnetic resonance imaging) was per-
formed in all patients presenting a new neurological deficit
after CEA. Other complications and events observed dur-
ing follow-up were recorded in accordance with the guide-
lines of the AdHoc Committee on Reporting Standards for
Cerebrovascular Disease, Society for Vascular Surgery/
North American Chapter of the International Society of
Cardiovascular Surgery.19
The study endpoints were long-term survival and
stroke-free survival.
Statistical analysis. All values are expressed as mean
SD. Continuous data were compared with the Student t
test (two-tailed) and categorical variables with Pearson 2
test (two-tailed) or Fisher exact test, as appropriate, calcu-
lating the odds ratio (OR) with 95% confidence intervals
(CIs). Cumulative life-table analyses (Kaplan-Meier) were
used to assess long-term survival and stroke-free survival
rates. Statistical significance was inferred for P .05. A Cox
proportional hazard multivariate analysis was used to deter-
y dise
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at univariate analysis might influence long-term outcome.
RESULTS
During the study period, 391 CEA procedures were
performed in 374 patients with asymptomatic severe ca-
rotid disease. Bilateral CEAs were performed in 40 (10.7%)
patients with at least one asymptomatic lesion and in 17
(4.5%) for bilateral asymptomatic disease. Bilateral CEAs
were planned at admission in 12 patients (correcting the
carotid with the greater degree of stenosis first and leaving
amean 4 weeks between procedures), whereas contralateral
CEA was indicated a mean of 25 3 months after the first
procedure in the other five cases. The patients’ demo-
graphic data and risk factors are summarized in Table I. The
mean age was 71 years (range, 40 to 93): 112 patients were
under 70 years old, 223 were 70 to 79 and 39 were 80 or
more. Almost two-thirds of the patients were males.
Perioperative (30-day) events. There were no peri-
operative deaths or strokes in this series. Three patients
(0.8%) had perioperative CHF, including twowith a history
of CHF, and one of them also had a postoperative nonfatal
MI. No hyperperfusion syndrome was observed in any of
the patients. Other surgical complications included 19
(4.8%) nerve injuries, and 18 (4.6%) neck hematomas re-
quiring surgical evacuation, with no further sequelae. Inju-
ries involved the cranial nerves in 3.3% of cases (13/391)
and the cervical nerves in 1.5% (6/391). There were 8
hypoglossal nerve injuries, 4 recurrent laryngeal nerve inju-
ries, 1 superior laryngeal nerve injury, 2 marginal mandib-
ular nerve injuries, 3 greater auricular nerve injuries, and 1
transverse cervical nerve injury. All nerve dysfunctions were
transient, and all recovered completely within 6 months of
CEA.
Long-term results. Long-term follow-up (mean, 6.1
years; range, 0.1 to 10.6 years) was obtained in 348 of 374
(93%) patients with an overall 365 (93.3%) CEAs (Table I).
Table I. Baseline characteristics of patients with asymptom
follow-up, and those lost to follow-up
Characteristics, n (%)
Patients who underwent CEA
n  374
Patie
Age (yrs), mean  SD 71.8  4.9
Male 247 (66)
Smoking 241 (64.4)
Hyperlipidemia 135 (36.1)
Diabetes mellitus 103 (27.5)
Hypertension 213 (56.9)
Cardiac disease 154 (41.2)
CKD 48 (12.8)
Pulmonary disease 63 (16.8)
AAA/PAD 216 (57.7)
Contralateral CO 42 (11.2)
Bilateral CEA 40 (10.7)
Intraluminal shunting 54 (13.8)
SD, Standard deviation; CEA, carotid endarterectomy; CKD, chronic kidne
carotid occlusion.Seventeen (4.8%) late deaths occurred, mainly of cardiac-related causes (cardiac disease, 12; cancer, 3; pancreatitis, 1;
car accident, 1). Kaplan-Meier analysis showed survival
rates at 1, 3, 5, and 10 years of 100%, 97.4%, 96.3%, and
85.7%, respectively (Fig).
Two (0.5%) late non-fatal strokes occurred: both
were clinically diagnosed as minor strokes and contralat-
eral to the revascularized hemisphere. Kaplan-Meier
analysis identified a stroke-free survival at 1, 3, 5, and 10
years of 99.7%, 97.1%, 95.6%, and 84.8 %, respectively
(Fig).
Table II shows a list of baseline characteristics with the
corresponding frequencies of late deaths and associated
univariate probabilities. Diabetes mellitus (OR, 5.1; 95%
disease who underwent CEA, patients who had complete
th a complete follow-up
n  348
Patients lost to follow-up
n  26 P value
71.1  5.6 71.3  4.4 1
227 (65.2) 20 (76.9) .225
233 (66.9) 8 (30.7) .01
129 (37.1) 6 (23.1) .152
98 (28.1) 5 (19.2) .373
208 (59.7) 5 (19.2) .01
146 (41.9) 8 (30.7) .264
47 (13.5) 1 (9.8) .228
59 (16.9) 4 (15.3) .237
209 (60) 7 (26.9) .01
39 (11.2) 3 (11.5) 1
38 (10.9) 2 (7.6) 1
51 (13.9) 3 (11.5) 1
ase; AAA/PAD, abdominal aortic aneurysm/peripheral artery disease; CO,
Fig. Kaplan-Meier curves show long-term survival and stroke-free
survival of asymptomatic patients with complete follow-up. Per-
centages on the right represent rates of survival and stroke-free
survival at 10 years. The standard error is less than 10% at each time
point in each curve. Range of standard errors is 0% to 4.6% for
survival and 0% to 4.7% for stroke-free survival, respectively. Raw
numbers of the patients at risk analyzed in each subset at each time
point are provided below the figure.atic
nts wiCIs 1.84-14.3; P .001), cardiac disease (OR, 4.8; 95%
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sion (OR, 3.6; 95% CIs  1.2-10.9; P  .040) were
significantly associated with a higher risk of death at 10
years. A history of abdominal aortic and/or peripheral
aneurysmal/atherosclerotic disease (AAA/PAD), either
conservatively or surgically treated, was marginally signifi-
cant as a positive risk factor for late death (OR, 3.2; 95%CIs
 0.9-11.5; P  .073). Male gender, older age, smoking,
hyperlipidemia, high systolic blood pressure, chronic kid-
ney or lung diseases, bilateral CEA, and intraluminal shunt-
ing were unassociated with late mortality. By Cox propor-
tional hazard multivariate analysis of the variables
considered (diabetes mellitus, cardiac disease, contralateral
carotid occlusion, and AAA/PAD), only diabetes mellitus
(P  .002) and cardiac disease (P  .005) revealed a
significant influence on long-term survival.
Univariate and multivariate analyses for stroke and
stroke-related death were inappropriate because the num-
ber of outcome events was too small and the number of
Table II. Univariate analysis of the association between
baseline demographic and clinical variables and long-term
risk of death after CEA
Characteristic Category
Death
n/N (%) P value
Age (years)
70 Yes 5/103 (4.8) 1
No 12/245 (4.9)
70 79 Yes 11/208 .863
No 6/140
 80 Yes 2/37 .699
No 15/311
Gender Female 6/121 (4.9) .830
Male 11/227 (4.8)
Smoking Yes 8/233 (3.4) .127
No 9/115 (7.8)
Hyperlipidemia Yes 7/129 (5.4) .918
No 10/219 (4.5)
Diabetes mellitus Yes 11/98 (11.2) .001
No 6/250 (2.4)
Hypertension Yes 12/208 (5.7) .450
No 5/140 (3.6)
Cardiac disease Yes 13/146 (8.9) .004
No 4/202 (1.9)
CKD Yes 3/47 (6.3) .712
No 14/301 (4.6)
Pulmonary disease Yes 2/59 (3.3) .747
No 15/289 (5.1)
AAA/PAD Yes 14/209 (6.7) .073
No 3/139 (2.1)
Contralateral CO Yes 5/39 (12.8) .040
No 12/309 (3.9)
Bilateral CEA Yes 1/38 (2.6) .706
No 16/310 (5.1)
Intraluminal shunting Yes 2/51 (3.9) 1
No 15/297 (5.0)
CEA, Carotid endarterectomy; CKD, chronic kidney disease; AAA/PAD,
abdominal aortic aneurysm/peripheral artery disease;CO, carotid occlusion.potential variables was relatively large.DISCUSSION
In this study, 374 consecutive patients with baseline
characteristics typical of the general population, including
those with comorbid conditions or particular anatomical
features underwent CEA for asymptomatic severe carotid
disease with no perioperative stroke or death. This outcome
correlates well with recently-published, large institution-
based studies report 30-day major stroke and death rates
ranging from 0.9% 20 to 1.9% 21 for patients undergoing
CEA for asymptomatic disease, and compares favorably
with the results of previous RCTs, such as the 2.3% of the
ACAS 1 and the 2.8% of the Asymptomatic Carotid Surgery
Trial (ACST).2
Although many authors have documented the durabil-
ity of the CEA procedure, showing an acceptably low
incidence of restenoses and late occlusions,14,15,22-24 out-
side the RCT setting, long-term survival and stroke-free
survival after CEA in asymptomatic patients have only been
examined in a few studies,13-17 usually with providing any
information on outcome vis-à-vis indications for sur-
gery.13-15 Data from the RCTs on long-term survival have
yet to become available, however: in the ACAS, the mean
follow-up was 2.6 years, and the ACST is still pursuing a
long-term follow-up.1,2
Among our 348 patients with a complete follow-up
after CEA for asymptomatic disease, the 5- and 10-year risk
of death was 3.7% and 14.3%, respectively, while the 5- and
10- year stroke-free survival rates were 95.6% and 84.8%,
respectively. These findings confirm what we already re-
ported in a previous experience15 on 1150 CEAs (302
CEAs with patching and 848 eversion CEAs) performed in
1000 patients (only a third of them asymptomatic) with a 5-
and 10- year risk of death of 7.2% and 12.8%, respectively.
These findings also correlate well with the 3- and 5-year risk
of death of 10% and 18% demonstrated by AbuRhama
et al,11 related to the natural history of the asymptomatic
carotid disease in a series of 420 patients who underwent
contralateral CEA for symptomatic or asymptomatic severe
carotid lesions. The outcome of our series contrasts, in-
stead, with the far worse results reported by other au-
thors.16,17 In a series of 631 CEAs (3.3% of them eversion
CEAs) performed for asymptomatic disease over a 10-year
period, Kragsterman et al17 recorded a 5- and 10-year risk
of death of 21.8% and 54.5%, respectively. They explained
the substantial drop in the long-term survival of their
patients, despite extremely low perioperative mortality
(0.5%), with an increasing annual mortality that negatively
affected longevity when compared with the expected sur-
vival for general population of the same age. No informa-
tion was available on stroke-free survival, however. Similar
results were reported by LaMuraglia et al16 in a series of
2236 CEA procedures (1987 patients; no eversion CEAs),
more than 60% of them performed for asymptomatic dis-
ease, with a 5- and 10-year risk of death of 27.6% and
55.3%, respectively. Here again, no information on long-
term stroke-free survival was forthcoming.
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reported in many series, and this has negatively influenced
decisions concerning CEA in asymptomatic older patients,
we found no such influence of older age in our study. The
mean age of our series was somewhat higher than in the
ACAS1 (67 years) or ACST 2 (68 years), but was compara-
ble with most of the series considered in reports on long-
term outcome after CEA.
Likely because diabetic patients comprised almost one
third of our asymptomatic cohort (28%), in agreement with
other studies,16,17 diabetes mellitus (P  .002) resulted an
independent predictor of late mortality. Another predictor
of reduced longevity was cardiac disease (P .005), which
is hardly surprising since cardiac disease has commonly
been identified as a risk factor with a significant impact on
long-term survival in such patients.16,17 These risk factors,
thus, should be taken into account when deciding whether
to perform this prophylactic procedure.
Our findings should be interpreted bearing in mind the
study’s limitations, however. First, although the data were
collected prospectively, the analysis is retrospective in na-
ture. Second, the globally-high incidence of prior major
vascular surgery and bilateral CEA, AAA, and PAD, and
occlusion of the contralateral carotid among our patients
probably reflects how most of them were identified and
recruited, ie, during assessment or follow-up for other
procedures and atherosclerotic lesions. These patients may,
therefore, represent a selected group with multiple athero-
sclerotic manifestations and this might alter the outcome,
though the potentially negative bias introduced clearly has
not affected the perioperative or long-term results. Third,
because our study population was limited to a group of 348
patients drawn from the initial set of 374, we cannot
exclude the possibility of the incidence of late fatal or
adverse events being higher, or confined to patients lost to
follow-up. Baseline risk factors comparison between our
cohort and the other patients showed, however, that the
patients with a complete follow-up were not healthier than
the others. Indeed, the higher prevalence of diabetes mel-
litus and high systolic blood pressure, and the preponder-
ance of cardiac and peripheral artery diseases and smokers in
our study cohort produced a bias towards a worse progno-
sis than for those without a complete follow-up, so the
patients lost to follow-up were unlikely to have experienced
a higher incidence of long-term adverse events. Fourth, our
study would have benefited from a comparison of the
long-term outcome in patients with asymptomatic severe
carotid disease followed up without CEA, but we believed
it would have been unethical to continue to follow patients
up clinically if CEAwas indicated. Finally, we are aware that
the nil perioperative stroke/mortality incidence and the
small number of late fatal or adverse events limit the reli-
ability of our results, but these are our results nonetheless.
CONCLUSION
Eversion CEA for asymptomatic severe disease proves a
safe and effective procedure in the general population,
including patients who would probably have been excludedfrom RCTs, with better perioperative results than those
achieved in the RCTs. Long-term survival and stroke-free
survival after CEA are important issues to consider when
deciding whether to recommend this prophylactic proce-
dure and, in this series, the results were extremely favorable.
The excellent long-term stroke-free survival was not trans-
lated into a longer patient survival, however, because none
of late deaths were related to neurological adverse events.
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